Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10289586 | 0.86 | HRH3 (0.36) | ALDH1A1TP53TSHRMAPK1HIF1A | |
| SCHEMBL20332702 | 0.76 | NOS3 (0.37) | KCNH2MCHR1ALDH1A1KDM4ETSHR | |
| SCHEMBL29475465 | 0.76 | NOS3 (0.37) | KCNH2MCHR1ALDH1A1KDM4ETSHR | |
| SCHEMBL23334546 | 0.74 | MAPT (0.42) | KCNH2MCHR1 | |
| SCHEMBL22584934 | 0.68 | KDM4E (0.36) | KCNH2ALDH1A1KDM4E | |
| SCHEMBL30202175 | 0.68 | KDM4E (0.36) | KCNH2ALDH1A1KDM4E | |
| SCHEMBL14174806 | 0.68 | ALDH1A1 (0.44) | KCNH2MCHR1ALDH1A1KDM4ETSHR | |
| SCHEMBL6384525 | 0.67 | ALDH1A1 (0.55) | KCNH2MCHR1ALDH1A1KDM4ETSHR | |
| SCHEMBL10888104 | 0.66 | MEN1 (0.41) | KCNH2MCHR1 | |
| SCHEMBL10893135 | 0.65 | KCNH2 (0.48) | KCNH2MCHR1ALDH1A1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053238-B2 | Benzimidazole derivatives, preparation methods and uses thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2021-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053238-B2 | Benzimidazole derivatives, preparation methods and uses thereof | CDK6, CDK4, CDK3 | KCNH2 4279/4885MCHR1 4523/4885ALDH1A1 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.